Medicines in Development: Heart Disease and Stroke Overview

Medicines in Development: Heart Disease and Stroke

Research in Indiana

Innovative Oncology Medicines Have Led to Impressive Gains in Patient Survivorship

WASHINGTON, D.C. (May 31, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement highlighting the value of innovative cancer medicines for patients, the economy and the U.S. health care system:

A Day In The Life

PhRMA Clinical Trial Principles Strengthen Authorship Standards

Washington, D.C. (September 18, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding efforts to enhance transparency in clinical research:

PhRMA Statement on 2013 Special 301 Report

WASHINGTON, D.C. (May 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice President Jay Taylor issued the following statement today:

Research and Hope Awards

Research & Hope Award Logo 2013

PhRMA Statement on Decision of the European General Court on EMA Disclosure of Company Data

WASHINGTON, D.C. (April 30, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement today:

Nearly 200 Medicines in Development for Mental Illnesses

Washington, D.C. (July 12, 2012) — America’s biopharmaceutical research companies are developing 187 innovative medicines to help the nearly 60 million patients in the United States who are suffering from some form of mental illness.

Pages

Subscribe to RSS - Innovation